Multiple Sclerosis (MS) is an autoimmune disease that occurs when the body’s immune system attacks the protective myelin who is covering the nerve cells. The lack of isolation causes inflammation, which interferes with communication between cells in the nervous system. This can lead to muscle weakness, poor coordination, problems with bowel and bladder, weakening of the eye vision, and cognitive difficulties. On March 28, 2017 U.S. Food and Drug Administration approved new treatment for multiple sclerosis.
Why is Multiple Sclerosis Difficult to Diagnose?
Around 2.3 million of people worldwide are suffering from multiple sclerosis. The condition sometimes develops years before the first symptoms appear, and it is usually diagnosed between the ages of 20 and 50 years. Multiple Sclerosis is difficult to diagnose because symptoms often subside before re-emerge. So far there is no cure for this disease only treatments which can reduce the symptoms, but do not always stop the progression of the disease.
How The New Treatment for Multiple Sclerosis Works
Now, a new drug called Ocrevus (ocrelizumab) is approved by the FDA (Food and drug administration in the US), and it is an immunosuppressive drug which instead of T-cells (that are targeted by other medicines for MS) targets a type of B-cell. Researchers believe that B-cells are instrumental in the destruction of myelin which causes the development of MS.
Ocrevus Can Reduce The Progress of The Disease
Compared to current standard treatments, the third phase of the clinical tests from the new drug indicated that relapse rates of the disease were reduced by 47% and inflammation by 95%. Most importantly of all it that the drug reduces the primary progressive forms of the disease – something that has not been observed in previous tests.
Originally developed by the company Genentech and purchased from Roche, the drug has the potential to change millions of lives -starting from patients who have long ago been diagnosed with MS to those who have just been diagnosed with multiple sclerosis.